Purchase this article with an account.
Meeyon Lee, Won Ki Lee; Photodynamic Therapy vs Combination Therapy in Polypoidal Choroidal Vasculopathy: Changes of Aqueous Vascular Endothelial Growth Factor. Invest. Ophthalmol. Vis. Sci. 2013;54(15):4507.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To investigate the influence of photodynamic therapy (PDT) and combination of PDT and ranibizumab on aqueous humor levels of vascular endothelial growth factor (VEGF) in polypoidal choroidal vasculopathy (PCV).
Prospective, randomized clinical trial. We included twenty eyes with treatment-naïve PCV and 20 eyes undergoing cataract surgery as controls. Eyes with PCV were randomized to treatment with PDT alone or to a combination of ranibizumab and PDT on same day. During 3 months of follow-up, retreatment was not performed. Aqueous humor samples were collected at baseline and at 1 week, 1 month and 3 months after treatment in PCV group and during cataract surgery in the control group. VEGF levels were measured using multiplex bead immunoassay.
At baseline, concentrations of VEGF were significantly increased in PCV eyes compared with control eyes. A significant decrease in VEGF levels were found at 1 week after PDT treatment (n=8), and at all time points after combination treatment (n=12). With combination treatment, VEGF levels were decreased to values below the detection limit in all eyes at 1 week and 1 month, and in 7 of 12 eyes at 3 months.
Decreased levels of VEGF detected 1 week after PDT for PCV seems to reflect acute damage of vascular endothelial cells, one of VEGF expression sites. Concomitant ranibizumab resulted in a further decrease in VEGF expression to negligible levels. This effect persisted for at least 1 month and as long as 3 months in more than half of the cases.
This PDF is available to Subscribers Only